ReviewFuture medicinal chemistry2026
Recent advances in the therapeutic potential of quinoline-piperazine hybrids.
Review in Future medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review summarizes the therapeutic potential of quinoline-piperazine hybrid molecules having no spacer/linker in between highlighting their potential therapeutic applications in various diseases that include viral infections, tuberculosis, malaria, fungal infections, microbial diseases, cancer, inflammatory disorders, and diabetes. The C-2 position of the quinoline ring is most frequently explored site for piperazine substitution, in comparison, substitutions at the C-4 and C-7 positions have been moderately investigated, whereas C-3 substitution remains relatively less explored and structure activity relationships associated with these hybrids have been explored broadly identifying key factors that influence their biological efficacy. Additionally, the electronic nature of the functional groups (i.e. electron donating or withdrawing) significantly influences the biological activity of the resulting molecules. Pharmacokinetic properties of the most potent quinoline-piperazine hybrids have been discussed. This review gives an insight into the designing and optimization of quinoline-piperazine hybrids as promising therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.